Forte Biosciences, Inc. Price & Performance (FBRX)

FORE Biotherapeutics presented new clinical data at AACR 2025, demonstrating that plixorafenib significantly reduced V600E mutant allele frequency in ctDNA for 85% of patients and showed pharmacodynamic activity in tumor biopsies. These results highlight plixorafenib’s potential as a differentiated therapy for BRAF-mutated tumors, strengthening its clinical profile.12

Forte Biosciences shares experienced high volatility today, trading between $4.91 and $7.18 before closing at $5.96. Despite a 62% drop over the past year, recent weeks saw increased search interest and a 45% six-month gain, reflecting renewed attention from retail and institutional investors alike.34

Forte Biosciences will hold its annual shareholder meeting on May 29, 2025. The company has posted a 39.8% return in the past week and maintains robust liquidity, with more cash than debt. Shareholder proposals for the meeting must be submitted by April 28, per updated company guidance.54